Bayer Targets Lupin Over Generic Natazia

Law360, New York (November 29, 2012, 12:39 PM EST) -- Bayer Pharma AG on Wednesday hit Lupin Ltd. with a patent infringement suit in Delaware federal court, seeking to block the India-based drugmaker's plans to market a generic version of its birth control pill Natazia.

Bayer alleges that Lupin's abbreviated new drug application with the U.S. Food and Drug Administration for oral contraceptive tablets that have the same active ingredients as Natazia pills infringe U.S. Patent Number 8,071,577, which does not expire until May 2026, according to the complaint.

“On information and belief, Lupin included in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.